Clinical trial · Interventional
Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)
Magnetic Resonance Elastography Score Reflecting Hepatic Fibrosis as an Independent Predictor for Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Therapy
NCT01447667CI-TRIAL-00071630MREcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine: * The efficacy of MRE score as a predictor of HCC recurrence within 2 years after RFA treatment * The efficacy of each indicator (MRE score, non-invasive serum markers) compared to the gold-standard histology score predicting hepatic fibrosis
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatic Fibrosis | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic resonance elastography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Magnetic resonance elastography
- description
- Magnetic resonance elastography before radiofrequency ablation therapy will be performed.
- interventionNames
- Procedure: Magnetic resonance elastography
Primary outcomes (1)
- measure
- Number of patients who experienced HCC recurrence after RFA
- timeFrame
- within 2 years after RFA procedure
- description
- To see whether MRE score reflecting hepatic fibrosis predicts the recurrence of HCC within 2 years after RFA treatment
Secondary outcomes (1)
- measure
- Sensitivity and specificity of each indicator of hepatic fibrosis compared to the gold-standard histology score
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed as single hypervascular hepatocellular carcinoma initially * AJCC stage I HCC * Child-Pugh class A * Planning radiofrequency ablation for HCC * Voluntary agreement for this study Exclusion Criteria: * Decreased kidney function (GFR \< 70 mL/min/kg) * Contraindication to MRI (pacemaker, defibrillator) * Contrast media hypersensitivity * Other primary malignancy * Acute viral hepatitis * Prior history of liver transplantation * Thrombosis in splenic vein or portal vein * Patients who were enrolled to other clinical trials within 4 weeks * Other severe chronic disease or psychiatric disease * Pregnant or milk-feeding women * Patients with coagulopathy, high risk of bleeding for the liver biopsy * Patients who disagree to participate in this study
References
Publications (0)
Data not yet available
No reference posted for this study.